These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 18487475)

  • 1. Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome.
    Undas A; Wiek I; Stêpien E; Zmudka K; Tracz W
    Diabetes Care; 2008 Aug; 31(8):1590-5. PubMed ID: 18487475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
    Konieczynska M; Fil K; Bazanek M; Undas A
    Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low fasting glucose is associated with enhanced thrombin generation and unfavorable fibrin clot properties in type 2 diabetic patients with high cardiovascular risk.
    Gajos G; Konieczynska M; Zalewski J; Undas A
    Cardiovasc Diabetol; 2015 May; 14():44. PubMed ID: 25928628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood clot properties, thrombin generation, and platelet activation in patients with dysglycemia and established atherosclerotic cardiovascular disease: The CASCARA study.
    Siniarski A; Gołębiowska-Wiatrak R; Malinowski KP; Gajos G
    Kardiol Pol; 2024; 82(6):617-624. PubMed ID: 38606741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unfavorably Altered Fibrin Clot Properties in Patients with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Association with Thrombin Generation and Eosinophilia.
    Mastalerz L; Celińska-Lӧwenhoff M; Krawiec P; Batko B; Tłustochowicz W; Undas A
    PLoS One; 2015; 10(11):e0142167. PubMed ID: 26540111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease.
    Neergaard-Petersen S; Hvas AM; Kristensen SD; Grove EL; Larsen SB; Phoenix F; Kurdee Z; Grant PJ; Ajjan RA
    Thromb Haemost; 2014 Dec; 112(6):1142-50. PubMed ID: 25187394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type 2 diabetes as a modifier of fibrin clot properties in patients with coronary artery disease.
    Bochenek M; Zalewski J; Sadowski J; Undas A
    J Thromb Thrombolysis; 2013 Feb; 35(2):264-70. PubMed ID: 23086579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denser plasma clot formation and impaired fibrinolysis in paroxysmal and persistent atrial fibrillation while on sinus rhythm: association with thrombin generation, endothelial injury and platelet activation.
    Drabik L; Wołkow P; Undas A
    Thromb Res; 2015 Aug; 136(2):408-14. PubMed ID: 26048399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prior simvastatin treatment is associated with reduced thrombin generation and platelet activation in patients with acute ST-segment elevation myocardial infarction.
    Pastuszczak M; Kotlarz A; Mostowik M; Zalewski J; Zmudka K; Undas A
    Thromb Res; 2010 May; 125(5):382-6. PubMed ID: 19631970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study.
    Szczepaniak P; Zabczyk M; Undas A
    PLoS One; 2015; 10(4):e0125069. PubMed ID: 25909989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyhedrocytes in blood clots of type 2 diabetic patients with high cardiovascular risk: association with glycemia, oxidative stress and platelet activation.
    Gajos G; Siniarski A; Natorska J; Ząbczyk M; Siudut J; Malinowski KP; Gołębiowska-Wiatrak R; Rostoff P; Undas A
    Cardiovasc Diabetol; 2018 Nov; 17(1):146. PubMed ID: 30466424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered plasma fibrin clot properties in patients with digestive tract cancers: links with the increased thrombin generation.
    Gronostaj K; Richter P; Nowak W; Undas A
    Thromb Res; 2013 Mar; 131(3):262-7. PubMed ID: 23273404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects.
    Undas A; Brozek J; Jankowski M; Siudak Z; Szczeklik A; Jakubowski H
    Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1397-404. PubMed ID: 16574890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy.
    Sumaya W; Wallentin L; James SK; Siegbahn A; Gabrysch K; Bertilsson M; Himmelmann A; Ajjan RA; Storey RF
    Eur Heart J; 2018 Apr; 39(13):1078-1085. PubMed ID: 29390064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is fibrin formation and thrombin generation increased during and after an acute coronary syndrome?
    Skeppholm M; Kallner A; Malmqvist K; Blombäck M; Wallén H
    Thromb Res; 2011 Nov; 128(5):483-9. PubMed ID: 21496882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrin clot properties and haemostatic function in men and women with type 1 diabetes.
    Tehrani S; Jörneskog G; Ågren A; Lins PE; Wallén H; Antovic A
    Thromb Haemost; 2015 Feb; 113(2):312-8. PubMed ID: 25318636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress.
    Undas A; Szułdrzynski K; Stepien E; Zalewski J; Godlewski J; Tracz W; Pasowicz M; Zmudka K
    Atherosclerosis; 2008 Feb; 196(2):551-7. PubMed ID: 17640649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered plasma fibrin clot properties and fibrinolysis in patients with multiple myeloma.
    Undas A; Zubkiewicz-Usnarska L; Helbig G; Woszczyk D; Kozińska J; Dmoszyńska A; Podolak-Dawidziak M; Kuliczkowski K
    Eur J Clin Invest; 2014 Jun; 44(6):557-66. PubMed ID: 24738991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interplay between elevated cellular fibronectin and plasma fibrin clot properties in type 2 diabetes.
    Konieczyńska M; Bryk AH; Malinowski KP; Draga K; Undas A
    Thromb Haemost; 2017 Aug; 117(9):1671-1678. PubMed ID: 28569923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy with high-dose statins reduces soluble P-selectin: The impact on plasma fibrin clot properties.
    Siudut J; Pudło J; Konieczyńska M; Polak M; Jawień J; Undas A
    Int J Cardiol; 2023 Feb; 373():110-117. PubMed ID: 36410546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.